Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 20   

Articles published

VRUS 0.0000
price chart
Federal Lawmakers Ask Gilead to Explain High Cost of Hepatitis C Drug
... Gilead acquired Sovaldi with the $11.2 billion purchase of Pharmasset Inc., the original developer, which expected to profitably sell the drug at a much lower price of $36,000, states the letter citing documents from the Securities and Exchange ...
Related articles »  
Gilead Close to Sending $84000 Drug to Poor Countries
�We didn't base it on our R&D costs, and we didn't base it on our acquisition costs,� he said, referring to Gilead's $11 billion purchase of Pharmasset Inc. to get the drug. �The most basic answer we give is the regimen cost was the same as the old ...
Gilead Sciences, Inc. (GILD) to Offer Low-cost Versions of Hepatitis C in ...  StockWise Daily
Gilead Update: Good News Keeps On Coming; Much Higher Share Prices ...  Seeking Alpha (registration)
Related articles »  
Neurovive Pharmaceutical: NeuroVive signs USD 150 m agreement with ...
The Company was founded by former executives of Pharmasset, Inc., which was acquired by Gilead Sciences in January 2012.
Related articles »  
UPDATE 1-Gilead says panel rejects Roche's claims on hep C drug
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Biotech Stocks Moves to Revive- Gilead Sciences, Inc. (NASDAQ:GILD), Ariad ...  eMarketsDaily
Why Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) Roars Back on Monday ...  iStreetWire
Related articles »  
NeuroVive inks US$ 150 mn pact with OncoBiopharma for outlicensing of ...
NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicencing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the development and commercialisation of NeuroVive's drug ...
Related articles »  
Notable 52-Week Highs and Lows of the Day 8/15: (ACHN) (GILD) (BITA) High ...
Gilead disclosed the following on Friday: In March 2013, Roche initiated an arbitration against us and Pharmasset, predecessor to Gilead Pharmasset LLC, regarding a 2004 collaboration agreement between Roche and Pharmasset. ... Bitauto Holdings ...
Achillion's hepatitis C drug shows promise in trial  WKZO
Related articles »  
Trader's Recap: Vale S.A. (NYSE:VALE), Gilead Sciences Inc. (NASDAQ:GILD ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Volume Buzz: Gilead Sciences Inc. (NASDAQ:GILD), Amicus Therapeutics, Inc ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Gilead Sciences: Despite This Year's Triumphs, Watch Out For Weaknesses ...  Seeking Alpha (registration)
Related articles »  
Traders Favorite: Gilead Sciences Inc. (NASDAQ:GILD), Achillion ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Related articles »  
Special News Alert: Gilead Sciences Inc. (NASDAQ:GILD), Amicus Therapeutics ...
Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012. Gilead started selling sofosbuvir under the ...
Related articles »